snowdeal logo

archives archives

{bio,medical} informatics

Friday, April 27, 2001

bookmark: connotea :: ::digg ::furl ::reddit ::yahoo::

find related articles. powered by google. The Boston Globe Celera Has Mouse Map Monopoly
" Celera Genomics Corp. will announce this morning that it has compiled a virtually complete gene map for the laboratory mouse -- but the company has decided against full scientific publication of the feat in order to preserve the data as a commercial product."

" The announcement means Venter's company is likely far ahead of publicly financed researchers in analyzing the genome of the laboratory mouse, an organism of vital import in research by drug companies, biotechnology companies and academic scientists. All these groups are prime markets for Celera, which sells access to genetic databases. Celera is "the only place to get the mouse genome," Venter said."
find related articles. powered by google. The Financial Times Genomics doubts hamper Celera
"Growing doubts about the importance of genomics in drug discovery are holding sales of Celera Genomics' database in check, chief executive Craig Venter said on Thursday.

The new scepticism is limiting Celera's sales to the pharmaceutical industry, even as its sales to academic institutions thrive.

The discovery that the human body has far fewer genes than once believed has thrown into question the "one gene, one protein, one drug" model, Mr Venter explained."

redux [03.10.01]
find related articles. powered by google. eCompany Future Boy: We've Mapped the Human Genome. Now What?
"With information on the genome now rapidly becoming available, the business models for companies that sell information about the genome, such as Celera and Incyte, may soon be outmoded. Biotech companies will then have to earn their stripes the old-fashioned way: by developing blockbuster drugs. Of course, proteomics companies could arise to sell information about proteins to other drug companies, but Strosberg thinks this is a flawed approach. Given his history, he should know. "Incyte's business model," he recalls, "was originally to be an information provider. That period is over. People will not pay as much for information as they used to because so much of it is now publicly available. Information is becoming a commodity." Instead of selling information about proteins, he is focusing Hybrigenics on using its proteomics information to develop drugs, either alone or in partnership with larger pharmaceutical companies."

[ rhetoric ]

Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.


[ search ]

[ outbound ]

biospace / genomeweb / bio-it world / scitechdaily / biomedcentral / the panda's thumb / / nodalpoint / flags and lollipops / on genetics / a bioinformatics blog / andrew dalke / the struggling grad student / in the pipeline / gene expression / free association / pharyngula / the personal genome / genetics and public health blog / the medical informatics weblog / linuxmednews / nanodot / complexity digest /

eyeforpharma /

nsu / nyt science / bbc scitech / newshub / biology news net /

informatics review / stanford / bmj info in practice / bmj info in practice /

[ schwag ]

look snazzy and support the site at the same time by buying some snowdeal schwag !

[ et cetera ]

valid xhtml 1.0?

This site designed by
Eric C. Snowdeal III .
© 2000-2005